You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聖湘生物(688289.SH)業績快報:2020年淨利暴增65.26倍至26.16億元
格隆匯 02-25 17:45

格隆匯2月25日丨聖湘生物(688289.SH)披露2020年度業績快報,報吿期內,公司實現營業總收入47.67億元,同比增長1204.67%;歸屬於母公司所有者的淨利潤26.16億元,同比增長6526.24%;歸屬於母公司所有者的扣除非經常性損益的淨利潤25.93億元,同比增長6786.23%。

報吿期內,面對全球突發疫情,公司積極響應,根據不同抗疫時期、不同應用場景需求、不同國情構建起了全場景化新冠檢測整體解決方案,全力以赴服務疫情防控。公司所開發的產品較好地滿足了市場需求,新冠核酸檢測試劑、核酸檢測儀器、相關耗材、檢驗服務等產品及服務的銷售業績取得重大突破,同時,公司儀器銷售及裝機增長進一步帶動公司全線試劑的增量銷售,2020年公司全年儀器累計發貨6122台,由此可以持續發揮新冠抗疫優勢,加速提升全線產品市場佔有率。綜合前述情況,公司2020年度整體銷售情況及經營業績較上一年度有了較大幅度的提升。

報吿期末,公司總資產為54.52億元,較上年同期增長748.58%;歸屬於母公司的所有者權益47.43億元,較上年同期增長750.74%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account